Early Stage Breast Cancer Virtual Roundtable Discussion - Scientific Interchange

Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

Joyce O’Shaughnessy, MD, discusses the findings from the phase 3 monarchE trial of adjuvant endocrine therapy with or without abemaciclib in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer.